From: Multicenter epidemiological survey of pneumatosis intestinalis in Japan
Characteristics | n | (%) |
---|---|---|
No. patients | 167 | |
Men/women | 87/80 | |
Median age of onset (years) | 65 (range 9–91) | |
Exposure to organic solvents | 2 | (1) |
Comobidities and/or past medical history | 141 | (84) |
Gastroduodenal diseases | 45 | (27) |
Inflammatory bowel disease | 16 | (10) |
Ulcerative colitis | 13 | (8) |
Crohn's disease | 2 | (1) |
Behcet's disease | 1 | (1) |
Carcinoma | 13 | (8) |
Esophegeal carcinoma | 1 | (1) |
Gastric carcinoma | 3 | (2) |
Colorectal carcinoma | 9 | (5) |
Colorectal polyp | 6 | (4) |
Bowel obstruction | 3 | (2) |
Others | 5 | (3) |
Diabetes mellitus | 31 | (19) |
Chronic lung disease | 28 | (17) |
Autoimmune disease | 30 | (18) |
Hypertension | 13 | (8) |
Heart disease | 11 | (7) |
Hepatobiliarypancreatic disease | 10 | (6) |
Kideny disease | 4 | (2) |
Others | 41 | (25) |
Medications used | 137 | (82) |
Corticosteroid | 45 | (27) |
Antidiabetics | 29 | (17) |
α-glucosidase inhibitors | 23 | (14) |
Others | 14 | (8) |
Gastric acid secretion inhibitors | 20 | (12) |
Proton pump inhibitors | 15 | (9) |
Histamine-2 receptor antagonists | 6 | (4) |
Antihypertensives | 19 | (11) |
Calcium antagonist | 10 | (6) |
β-blocker | 8 | (5) |
Angiotensin II receptor blocker | 9 | (5) |
Angiotensin converting enzyme inhibitor | 1 | (1) |
α-blocker | 1 | (1) |
Immunosuppressants | 16 | (10) |
5-aminosalicylates or salicylazosulfapyridine | 15 | (9) |
Statins/ezetimib/fibrates | 14 | (8) |
Antithrombotics | 12 | (7) |
Anticoagulants | 4 | (2) |
Antiplatelets | 9 | (5) |
Laxatives* | 10 | (6) |
Anti-cancer agents | 9 | (5) |
Herbal medicine | 7 | (4) |
Allopurinol/benzbromaron | 3 | (2) |
Others | 44 | (26) |